Isotretinoin and the risk of inflammatory bowel disease and irritable bowel syndrome: A large-scale global study

3Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Introduction: Risk of inflammatory bowel disease under isotretinoin is a scope of a long-standing controversy. The burden of isotretinoin-related irritable bowel syndrome has not been investigated. Objective: To evaluate the risk of Crohn's disease, ulcerative colitis (UC), and irritable bowel syndrome in patients with acne starting isotretinoin vs oral antibiotics treatment. Methods: A global population-based retrospective cohort study assigned 2 groups of patients with acne initiating isotretinoin (n = 77,005) and oral antibiotics (n = 77,005). Comprehensive propensity-score matching was conducted. Results: The lifetime risk of Crohn's disease (hazard ratio [HR], 1.05; 95% CI, 0.89-1.24; P = .583) and UC (HR, 1.13; 95% CI, 0.95-1.34; P = .162) was comparable between study groups, whereas the lifetime risk of irritable bowel syndrome was lower in isotretinoin-prescribed patients (HR, 0.82; 95% CI, 0.76-0.89; P

Cite

CITATION STYLE

APA

Kridin, K., & Ludwig, R. J. (2023). Isotretinoin and the risk of inflammatory bowel disease and irritable bowel syndrome: A large-scale global study. Journal of the American Academy of Dermatology, 88(4), 824–830. https://doi.org/10.1016/j.jaad.2022.12.015

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free